Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02678182 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Planning Treatment for Oesophago-gastric Cancer: a Maintenance Therapy Trial

Study acronym: PLATFORM
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Mar 2025 to Apr 17, 2025v9
  2. Re-verified, no change to tracked fieldsv8
  3. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 924 to confirmed 494
    • Interventions: Capecitabine (Drug), MEDI4736 (Drug), Ramucirumab (Drug), Rucaparib (Drug), Trastuzumab (Drug) to Capecitabine (Drug), MEDI4736 (Durvalumab) (Drug), Ramucirumab (Drug), Rucaparib (Drug), Trastuzumab (Drug)
    • Site details revised
    v7
  4. Primary completion date: Mar 2023 to Mar 2025v6 Show 5 more changesShow less
    • Study completion date: Jun 2025 to Jun 2027
    • Eligibility criteria shortened, about 78 words
    • Study description expanded, about 22 words
    • Site contact updated
    • Collaborators: 3 to 4
  5. Primary completion date: Feb 2020 to Mar 2023v5 Show 7 more changesShow less
    • Enrollment target: 770 to 924
    • Study completion date: Aug 2021 to Jun 2025
    • Interventions: Capecitabine (Drug), MEDI4736 (Drug), Rucaparib (Drug), Trastuzumab (Drug) to Capecitabine (Drug), MEDI4736 (Drug), Ramucirumab (Drug), Rucaparib (Drug), Trastuzumab (Drug)
    • Eligibility criteria expanded, about 251 words
    • Site contact updated
    • Collaborators: 2 to 3
    • Study arms: 5 to 6
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revisedv4
  2. Primary completion date: Feb 2018 to Feb 2020v3 Show 7 more changesShow less
    • Enrollment target: 616 to 770
    • Study completion date: Feb 2020 to Aug 2021
    • Interventions: Capecitabine (Drug), MEDI4736 (Drug), Trastuzumab (Drug) to Capecitabine (Drug), MEDI4736 (Drug), Rucaparib (Drug), Trastuzumab (Drug)
    • Eligibility criteria expanded, about 19 words
    • Collaborators: 1 to 2
    • Study arms: 4 to 5
    • Study description expanded, about 2 words
  3. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the efficacy of maintenance therapies following completion of standard first-line chemotherapy in patients with locally advanced or metastatic HER-2 positive or HER-2 negative oesophago-gastric adenocarcinomas.
Trial Details
NCT Number NCT02678182
Lead Sponsor Royal Marsden NHS Foundation Trust
Collaborators: MedImmune LLC, Clovis Oncology, Inc., Eli Lilly and Company, AstraZeneca
Conditions
(from sponsor)		 Adenocarcinoma of the Oesophagus, Adenocarcinoma of the Gastro-oesophageal Junction, Adenocarcinoma of the Stomach
Enrollment 494 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov